Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $103.98 in the prior trading day, Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $102.99, down -0.95%. In other words, the price has decreased by -$0.95 from its previous closing price. On the day, 0.6 million shares were traded.
Ratios:
Our goal is to gain a better understanding of AXSM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.96 and its Current Ratio is at 2.03. In the meantime, Its Debt-to-Equity ratio is 3.97 whereas as Long-Term Debt/Eq ratio is at 3.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on April 07, 2025, initiated with a Buy rating and assigned the stock a target price of $200.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $176.
Mizuho reiterated its Outperform rating for the stock on December 31, 2024, while the target price for the stock was revised from $124 to $122.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 27 ’25 when Jacobson Mark L. sold 20,673 shares for $104.66 per share. The transaction valued at 2,163,636 led to the insider holds 5,783 shares of the business.
Jacobson Mark L. sold 20,000 shares of AXSM for $2,069,000 on May 28 ’25. The Chief Operating Officer now owns 5,783 shares after completing the transaction at $103.45 per share. On May 28 ’25, another insider, Coleman Mark, who serves as the Director of the company, bought 3,750 shares for $103.43 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 11.73 while its Price-to-Book (P/B) ratio in mrq is 95.27.
Stock Price History:
Over the past 52 weeks, AXSM has reached a high of $139.13, while it has fallen to a 52-week low of $64.11. The 50-Day Moving Average of the stock is -5.88%, while the 200-Day Moving Average is calculated to be 1.97%.
Shares Statistics:
A total of 49.22M shares are outstanding, with a floating share count of 40.44M. Insiders hold about 17.86% of the company’s shares, while institutions hold 76.19% stake in the company.
Earnings Estimates
A comprehensive evaluation of Axsome Therapeutics Inc (AXSM) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.91, with high estimates of -$0.52 and low estimates of -$1.34.
Analysts are recommending an EPS of between -$2.58 and -$4.45 for the fiscal current year, implying an average EPS of -$3.74. EPS for the following year is $1.14, with 11.0 analysts recommending between $4.8 and -$2.97.
Revenue Estimates
17 analysts predict $140.02M in revenue for the current quarter. It ranges from a high estimate of $148.1M to a low estimate of $135.1M. As of the current estimate, Axsome Therapeutics Inc’s year-ago sales were $87.17MFor the next quarter, 17 analysts are estimating revenue of $162.56M. There is a high estimate of $181.46M for the next quarter, whereas the lowest estimate is $143.4M.
A total of 18 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $663.7M, while the lowest revenue estimate was $558.6M, resulting in an average revenue estimate of $613.5M. In the same quarter a year ago, actual revenue was $385.69MBased on 18 analysts’ estimates, the company’s revenue will be $979.62M in the next fiscal year. The high estimate is $1.15B and the low estimate is $777.5M.
